• 1
    Bosman FT, Carneiro F, Hruban RH, Theise ND. World Health Organization (WHO) Classification of Tumours of the Digestive System. 4th ed. Geneva, Switzerland: WHO Press; 2010.
  • 2
    Solcia E, Kloppel G, Sobin LH. Histological Typing of Endocrine Tumours. New York: Springer; 2000.
  • 3
    Strosberg J, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39:799-800.
  • 4
    Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2009;35:228-236.
  • 5
    Kloppel G, Heitz PU, Capella C, Solcia E. Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg. 1996;20:132-141.
  • 6
    Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. Cancer. 1997;79:1729-1736.
  • 7
    Lee SS, Lee JL, Ryu MH, et al. Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol. 2007;46:846-851.
  • 8
    Brennan SM, Gregory DL, Stillie A, Herschtal A, Manus MM, Ball DL. Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer. 2010;116:888-895.
  • 9
    Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol. 2004;22:2730-2739.
  • 10
    Brenner B, Tang LH, Shia J, Klimstra DS, Kelsen DP. Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol. 2007;34:43-50.
  • 11
    Wong YNS, Jack RH, Mak V, Henrik M, Davies EA. The epidemiology and survival of extra-pulmonary small cell carcinoma in South East England, 1970–2004 [serial online]. BMC Cancer. 2009;9:209.
  • 12
    Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of 2 decades of cancer registry. Eur J Cancer. 2013;49:1975-1983.
  • 13
    Cicin I, Karagol H, Uzunoglu S, et al. Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study. Cancer. 2007;110:1068-1076.
  • 14
    Terashima T, Morizane C, Hiraoka N, et al. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology. 2012;96:324-332.
  • 15
    Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011;11:4617-4622.
  • 16
    Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO grade 3): the NORDIC NEC study. Ann Oncol. 2013;24:152-160.
  • 17
    Hentic O, Hammel P, Couvelard A, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19:751-757.
  • 18
    Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Incidence—SEER 9 Regs Research Data, November 2011 submission (1973–2010). Bethesda, MD: National Cancer Institute, Cancer Statistics Branch; 2013.
  • 19
    Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
  • 20
    Lepage C, Ciccolallo L, De Angelis R, Bouvier RD, Faivre J, Gatta G. European disparities in malignant digestive endocrine tumours survival. Int J Cancer. 2010;126:2928-2934.
  • 21
    Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer. 2004;90:1720-1726.
  • 22
    Machida N, Yamaguchi T, Kasuga A, et al. Multicenter retrospective analysis of systemic chemotherapy for advanced poorly differentiated neuroendocrine carcinoma of the digestive system [abstract]. J Clin Oncol. 2012;30(15S). Abstract 4046.
  • 23
    Walter T, Tougeron D, Manfredi S, et al. Clinical characteristics in 127 patients with advanced G3 gastrointestinal neuroendocrine carcinoma: the FFCD-GTE national cohort study [abstract 2464]. Paper presented at: European Cancer Congress 2013; September 27 to October 1, 2013; Amsterdam, the Netherlands. Available at:
  • 24
    Cho MY, Kim JM, Sohn JH, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000–2009: multicenter study. Cancer Res Treat. 2012;44:157-165.
  • 25
    Kang H, O'Connell JB, Leonardi MJ. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 2007;22:183-189.
  • 26
    Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32:719-731.
  • 27
    La Rosa S, Marando A, Furlan D, Sahnane N, Capella C. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012;36:601-611.
  • 28
    Maru DM, Khurana H, Rashid A, et al. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008;32:1404-1411.
  • 29
    Smith JD, Reidy DL, Weiser M, et al. Review of 126 high grade neuro-endocrine carcinomas of the colon and rectum [abstract]. Pancreas. 2013;42:382.
  • 30
    Vortmeyer AO, Lubensky IA, Merino MJ, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst. 1997;89:1448-1453.
  • 31
    Kim KM, Kim MJ, Cho BK, Choi SW, Rhyu MG. Genetic evidence for the multi-step progression of mixed glandular-neuroendocrine gastric carcinomas. Virchows Arch. 2001;440:85-93.
  • 32
    Ubiali A, Benetti A, Papotti M, Villanacci V, Rindi G. Genetic alterations in poorly differentiated endocrine colon carcinomas developing in tubulo-villous adenomas: a report of 2 cases. Virchows Arch. 2001;439:776-781.
  • 33
    Pizzi S, Azzonli C, Bassi D, Bottarellei L, Milione M, Bordi C. Genetic alterations on poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer. 2003;98:1273-1282.
  • 34
    Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumours. Am J Surg Pathol. 2012;36:173-184.
  • 35
    Karkouche R, Bachet JB, Sandrini J, et al. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. Eur J Gastroenterol Hepatol. 2012;24:1430-1437.
  • 36
    Kulke MH. Are neuroendocrine tumors going mainstream? J Clin Oncol. 2013;31:404-405.
  • 37
    Velayoudom-Cephise FL, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20:649-657.
  • 38
    Scoazec JY, Couvelard A, Monges G, et al. Well-differentiated grade 3 digestive neuroendocrine tumors: myth or reality? The PRONET Study Group [abstract]. J Clin Oncol. 2012;30:(15S). Abstract 4129.
  • 39
    Basturk O, Yang Z, Tang LH, et al. Increased (>20%) KI67 proliferation index in morphologically well differentiated pancreatic neuroendocrine tumors (pannets) correlates with decreased overall survival. 102nd USCAP (United States and Canadian Academy of Pathology) Annual Meeting, March 2–8, 2013 Baltimore, Maryland, USA [abstract]. Lab Invest. 2013;93(suppl 1). Abstract 423A.
  • 40
    Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
  • 41
    Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372-2377.
  • 42
    Korse CM, Taal BG, Vincent A, et al. Choice of markers in patients with neuroendocrine tumours is dependent on histological grade. Eur J Cancer. 2012;48:662-671.
  • 43
    Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 1998;78:1102-1107.
  • 44
    Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978-985.
  • 45
    Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy and 18F-FDG PET. J Nucl Med. 2010;51:704-712.
  • 46
    Faggiano A, Sabourin JC, Ducreux M, et al. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas. Cancer. 2007;110:265-274.
  • 47
    Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004;47:163-169.
  • 48
    Fujii H, Aotake T, Horiuchi T, Chiba Y, Imamura Y, Tanaka K. Small cell carcinoma of the gallbladder: a case report and review of 53 cases in the literature. Hepatogastroenterology. 2001;48:1588-1593.
  • 49
    Strosberg J, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer staging classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29:3044-3049.
  • 50
    Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain. Ann Oncol. 2010;21:1794-1803.
  • 51
    Olsen IH, Sorensen JB, Federspiel B, et al. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas [serial online]. ScientificWorldJournal 2012:170496, 2012.
  • 52
    Hadoux J, Planchard D, Guigay J, et al. Oxalipatin-based chemotherapy for grade 3 neuroendocrine carcinoma after failure of platinum-based chemotherapy [abstract J2]. Paper presented at: 10th Annual European Neuroendocrine Tumor Society (ENETS) Conference; March 6–8, 2013; Barcelona, Spain. Available at:
  • 53
    Casas F, Ferrer F, Farrus B, Casals J, Biete A. Primary small cell carcinoma of the oesophagus: a review of the literature with emphasis on therapy and prognosis. Cancer. 1997;80:1366-1372.
  • 54
    Ku GY, Minsky BD, Rusch VW, Bains M, Kelsen DP, Ilson DH. Small-cell carcinoma of the oesophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Ann Oncol. 2008;19:533-537.
  • 55
    Sorbye H. Neoadjuvant chemotherapy in extra-pulmonary neuroendocrine carcinoma, neoadjuvant chemotherapy. In: Bathe OF, ed. Current Applications in Clinical Practice. Rijeka, Croatia: In Tech; 2012:41-58. Available at:
  • 56
    Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumours. Pancreas. 2013;42:557-577.
  • 57
    Cho CS, Labow DM, Tang L, et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer. 2008;113:126-134.
  • 58
    Saxena A, Chua TC, Sarkar A, et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery. 2011;149:209-220.
  • 59
    Sorbye H, Westre B, Horn A. Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma. Eur J Surg Oncol. 2007;33:1209-1210.
  • 60
    Power DG, Asmis TR, Tang LH, Brown K, Kemeny NE. High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease. Med Oncol. 2011;28(suppl 1):S169-S174.
  • 61
    Eriksson B, Annibale B, Bajetta E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology. 2009;90:214-219.
  • 62
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Vol10. Fort Washington, PA: National Comprehensive Cancer Network; 2010.
  • 63
    Janson ET, Sorbye H, Welin S, et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol. 2010;49:740-756.
  • 64
    Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227-232.
  • 65
    Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351-1355.
  • 66
    Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma. J Clin Oncol. 2006;24:3548-3554.
  • 67
    Mani MA, Shroff RT, Jacobs C, et al. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma [abstract]. J Clin Oncol. 2008;26:15S. Abstract 15550.
  • 68
    Lu ZH, Li J, Lu M, Zhang XT, et al. Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas [serial online]. Med Oncol. 2013;30:664.
  • 69
    Ezziddin S, Opitz M, Attassi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38:459-466.
  • 70
    Garske U, Sandstrom M, Johansson S, et al. Lessons on tumour response: imaging during therapy with 177Lu-DOTA-octreotate. A case report on a patient with a large volume of poorly differentiated neuroendocrine carcinoma. Theranostics. 2012;2:459-471.
  • 71
    Fazio N, Grana C, Pelosi G, et al. Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma. Acta Oncol. 2006;45:627-629.
  • 72
    Shida T, Kishimoto T, Furuya M, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumours. Cancer Chemother Pharmacol. 2010;65:889-893.
  • 73
    Catena L, Bajetta E, Milione M, et al. Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges. Target Oncol. 2011;6:65-68.
  • 74
    Bollard J, Couderc C, Blanc M, et al. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas. Neuroendocrinology. 2013;97:331-340.